The Transcribed-Ultra Conserved Regions: Novel Non-Coding RNA Players in Neuroblastoma Progression

Overview

Journal Noncoding RNA

Date 2019 Jun 7

PMID 31167408

Citations 6

Authors

Nithya Mudgapalli

Brianna P Shaw

Srinivas Chava

Kishore B Challagundla

Affiliations

Soon will be listed here.

Abstract

The Transcribed-Ultra Conserved Regions (T-UCRs) are a class of novel non-coding RNAs that arise from the dark matter of the genome. T-UCRs are highly conserved between mouse, rat, and human genomes, which might indicate a definitive role for these elements in health and disease. The growing body of evidence suggests that T-UCRs contribute to oncogenic pathways. Neuroblastoma is a type of childhood cancer that is challenging to treat. The role of non-coding RNAs in the pathogenesis of neuroblastoma, in particular for cancer development, progression, and therapy resistance, has been documented. Exosmic non-coding RNAs are also involved in shaping the biology of the tumor microenvironment in neuroblastoma. In recent years, the involvement of T-UCRs in a wide variety of pathways in neuroblastoma has been discovered. Here, we present an overview of the involvement of T-UCRs in various cellular pathways, such as DNA damage response, proliferation, chemotherapy response, ( ()) amplification, gene copy number, and immune response, as well as correlate it to patient survival in neuroblastoma.

Citing Articles

Epigenetic tuning of tumour-associated macrophages (TAMs): a potential approach in hepatocellular carcinoma (HCC) immunotherapy.

Helal I, Kamal M, Abd El-Aziz M, El Tayebi H Expert Rev Mol Med. 2024; 26:e18.

PMID: 39320855 PMC: 11440614. DOI: 10.1017/erm.2024.9.

The crosstalk between non-coding RNAs and cell-cycle events: A new frontier in cancer therapy.

Pathania A, Chava H, Balusu R, Pasupulati A, Coulter D, Challagundla K Mol Ther Oncol. 2024; 32(2):200785.

PMID: 38595981 PMC: 10973673. DOI: 10.1016/j.omton.2024.200785.

Exosome regulation of immune response mechanism: Pros and cons in immunotherapy.

Milon Essola J, Zhang M, Yang H, Li F, Xia B, Mavoungou J Bioact Mater. 2023; 32:124-146.

PMID: 37927901 PMC: 10622742. DOI: 10.1016/j.bioactmat.2023.09.018.

miR-15a and miR-15b modulate natural killer and CD8T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma.

Pathania A, Prathipati P, Olwenyi O, Chava S, Smith O, Gupta S Mol Ther Oncolytics. 2022; 25:308-329.

PMID: 35663229 PMC: 9133764. DOI: 10.1016/j.omto.2022.03.010.

New insights into exosome mediated tumor-immune escape: Clinical perspectives and therapeutic strategies.

Pathania A, Prathipati P, Challagundla K Biochim Biophys Acta Rev Cancer. 2021; 1876(2):188624.

PMID: 34487817 PMC: 8595777. DOI: 10.1016/j.bbcan.2021.188624.

References

Brodeur G . Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; 3(3):203-16. DOI: 10.1038/nrc1014. View

Vassilev L, Vu B, Graves B, Carvajal D, Podlaski F, Filipovic Z . In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-8. DOI: 10.1126/science.1092472. View

Bejerano G, Pheasant M, Makunin I, Stephen S, Kent W, Mattick J . Ultraconserved elements in the human genome. Science. 2004; 304(5675):1321-5. DOI: 10.1126/science.1098119. View

Bernstein B, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey D, Huebert D . Genomic maps and comparative analysis of histone modifications in human and mouse. Cell. 2005; 120(2):169-81. DOI: 10.1016/j.cell.2005.01.001. View

Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N . Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol. 2005; 23(10):2280-99. DOI: 10.1200/JCO.2005.06.104. View

Luksch R, Podda M, Gandola L, Polastri D, Piva L, Castellani R . Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haemopoietic stem cell transplantation to consolidate primary treatment. Br J Cancer. 2005; 92(11):1984-8. PMC: 2361794. DOI: 10.1038/sj.bjc.6602615. View

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

Bernstein B, Mikkelsen T, Xie X, Kamal M, Huebert D, Cuff J . A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell. 2006; 125(2):315-26. DOI: 10.1016/j.cell.2006.02.041. View

Van Maerken T, Speleman F, Vermeulen J, Lambertz I, De Clercq S, Smet E . Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res. 2006; 66(19):9646-55. DOI: 10.1158/0008-5472.CAN-06-0792. View

10.

Lazcoz P, Munoz J, Nistal M, Pestana A, Encio I, Castresana J . Loss of heterozygosity and microsatellite instability on chromosome arm 10q in neuroblastoma. Cancer Genet Cytogenet. 2007; 174(1):1-8. DOI: 10.1016/j.cancergencyto.2006.08.014. View

11.

Lujambio A, Esteller M . CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle. 2007; 6(12):1455-9. View

12.

Mikkelsen T, Ku M, Jaffe D, Issac B, Lieberman E, Giannoukos G . Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature. 2007; 448(7153):553-60. PMC: 2921165. DOI: 10.1038/nature06008. View

13.

Calin G, Liu C, Ferracin M, Hyslop T, Spizzo R, Sevignani C . Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 2007; 12(3):215-29. DOI: 10.1016/j.ccr.2007.07.027. View

14.

Schulte J, Horn S, Otto T, Samans B, Heukamp L, Eilers U . MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer. 2007; 122(3):699-704. DOI: 10.1002/ijc.23153. View

15.

De Bernardi B, Gambini C, Haupt R, Granata C, Rizzo A, Conte M . Retrospective study of childhood ganglioneuroma. J Clin Oncol. 2008; 26(10):1710-6. DOI: 10.1200/JCO.2006.08.8799. View

16.

Rossi S, Sevignani C, Nnadi S, Siracusa L, Calin G . Cancer-associated genomic regions (CAGRs) and noncoding RNAs: bioinformatics and therapeutic implications. Mamm Genome. 2008; 19(7-8):526-40. DOI: 10.1007/s00335-008-9119-8. View

17.

Lujambio A, Esteller M . How epigenetics can explain human metastasis: a new role for microRNAs. Cell Cycle. 2009; 8(3):377-82. DOI: 10.4161/cc.8.3.7526. View

18.

Guttman M, Amit I, Garber M, French C, Lin M, Feldser D . Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009; 458(7235):223-7. PMC: 2754849. DOI: 10.1038/nature07672. View

19.

Tonini G . Treatment of neuroblastoma: from cellular to molecular therapy. Curr Pharm Des. 2009; 15(4):422-3. DOI: 10.2174/138161209787315828. View

20.

Corcoran D, Pandit K, Gordon B, Bhattacharjee A, Kaminski N, Benos P . Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data. PLoS One. 2009; 4(4):e5279. PMC: 2668758. DOI: 10.1371/journal.pone.0005279. View